Answers are grounded in this paper and cite their sources.
BACKGROUND: The main objective was to evaluate the efficacy and safety of anti-VEGF Brolucizumab injection in vitrectomised eyes for post-vitrectomy recalcitrant macular edema in patients with nAMD/ PCV and recalcitrant diabetic macular edemas as per pro-re-nata protocol. PATIENTS AND METHODS: A prospective, multi-centric non-randomised interventional study was performed where intravitreal injection of Brolucizumab was administered for post-vitrectomy recalcitrant macular edema as per pro-re-nata protocol. Vitrectomy was performed for sub-macular haemorrhage (Group A) and recalcitrant diabetic macular oedema (Group B). MAIN OUTCOMES MEASURED: Pre- and post-injection BCVA and Central Foveal Thickness (CFT) were noted at 4, 12, 24, 36, 52, and 76 weeks. RESULTS: Eighty-one intravitreal injections of Brolucizumab were given in 51 eyes. The BCVA improved from pre-injection LogMAR 0.80 ± 0.32 to 6-month post-injection 0.65 ± 0.23 (Group A, p-value < 0.001, 95% CI) and LogMAR 0.70 ± 0.37 to 0.60 ± 0.34 (Group B, p = 0.378, 95% CI). Significant reduction in CFT noted from pre-injection 367.75 ± 124.12 microns to 6-month post-injection 291.09 ± 81.42 micron (A, p = 0.001, 95% CI) and from 468.45 ± 145.69 micron to 342.19 ± 117.91 micron (B, p = 0.002, 95% CI). CONCLUSION: Brolucizumab may have the potential to be durable, effective and safe in vitrectomised eyes in both post-nAMD and diabetic patients.
No takes yet. Share an insight, caveat, or question.
Boral et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: